In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)